<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04794777</url>
  </required_header>
  <id_info>
    <org_study_id>PSMA recidiv</org_study_id>
    <nct_id>NCT04794777</nct_id>
  </id_info>
  <brief_title>Comparing &quot;Salvage&quot; Radiotherapy and Individualized PSMA PET/CT Targeted Treatment in With Relapsing Prostate Cancer</brief_title>
  <official_title>A Randomized Trial Comparing Conventional &quot;Salvage&quot; Radiotherapy and Individualized 68Ga-PSMA-11 or 18F-PSMA-1007 PET/CT Targeted Treatment in Patients With Biochemical Recurrence After Prostate Cancer Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stefan Carlsson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Less than 50% of patients receiving salvage radiation therapy (SRT) to the pelvis as&#xD;
      treatment for prostate cancer relapsing after surgery will achieve undetectable Prostate&#xD;
      Specific Antigen (PSA) levels. Despite SRT, two-thirds of patients will again develop&#xD;
      elevated PSA, 20% will have distant metastases, and 10% will die from prostate cancer within&#xD;
      10 years. The reason for this is probably preexisting distant metastasis and lymph node&#xD;
      metastasises which need to better targeted directly. Additionally , there are well known&#xD;
      permanent side effects to SRT.&#xD;
&#xD;
      Standard imaging techniques have poor sensitivity detecting recurrence when PSA is below 1.0&#xD;
      ng/ml. The surface protein Prostate-specific membrane antigen (PSMA) is overexpressed on&#xD;
      prostate cancer cells and 68Gallium (68Ga)- and 18Fluorine (18F)-targeted radioligands have&#xD;
      been developed. PSMA PET/CT is used increasingly but there is limited data of its impact.&#xD;
&#xD;
      In this study patients with biochemical relapse of prostate cancer after surgery are&#xD;
      randomised to the control or experimental group (1:2) and undergo a PSMA PET/CT scan. The&#xD;
      experimental group receives individualised therapy based on the result of the PET/CT. The&#xD;
      control group receives standard salvage therapy and the result of the PET/CT is blinded. The&#xD;
      patients are followed-up with PSA test and quality of life questionnaires.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 30, 2018</start_date>
  <completion_date type="Anticipated">October 30, 2027</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2027</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary progression free survival</measure>
    <time_frame>Throughout the study, approximately 10 years.</time_frame>
    <description>Number of patients with progress defined by Prostate-Specific Antigen (PSA) measurement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to metastasis</measure>
    <time_frame>At 5, 7 and 10 years</time_frame>
    <description>Time to documented metastasis of prostate cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate cancer specific survival</measure>
    <time_frame>At 5, 7 and 10 years</time_frame>
    <description>Time to prostate cancer specific death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to secondary treatment</measure>
    <time_frame>At 5, 7 and 10 years</time_frame>
    <description>Time to need for secondary treatment for prostate cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in quality of life recorded using Patient Reported Outcome Measure (PROM)</measure>
    <time_frame>Baseline, 6, 12, 36 and 60 months after completed treatment.</time_frame>
    <description>A modified version of the PSMA questionnaire developed by the National Prostate Cancer Register</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individualised therapy based on results of the PSMA PET/CT.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard salvage therapy. Results of PSMA PET/CT blinded.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Individualised therapy</intervention_name>
    <description>Group I - No uptake: treated with conventional SRT against the prostate bed. Group II -Uptake only in the prostate bed: will receive intensity modulated RT (IMRT) including Volumetric Modulated Arc Therapy (VMAT) for prostate bed with simultaneous-integrated boost (SIB) to the PET positive uptake in the prostate bed.&#xD;
Group III - Uptake in the prostate bed and involvement of regional lymph nodes in the pelvis: will be treated as Group II plus VMAT for the pelvic lymph nodes with SIB to the PET positive lymph nodes or pelvic lymph nodes salvage lymph node dissection (SLND).&#xD;
Group IV - Uptake in regional lymph nodes only: will be treated with VMAT for the pelvic lymph nodes with SIB to the PET positive lymph nodes or pelvic lymph nodes SLND.&#xD;
Group V - Uptake in extra-pelvic lymph nodes or bone metastasis: systemic treatment instead of surgery or radiation. Local treatment with surgery or radiation is acceptable if curative intention.</description>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Standard salvage therapy</intervention_name>
    <description>Standard salvage radiotherapy</description>
    <arm_group_label>Control arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients previously treated for prostate cancer with radical prostatectomy and now&#xD;
             having a biochemical recurrence (BCR) defined as: PSA &gt;0.2 &lt;2.0 ng/mL, and increasing&#xD;
             measured twice.&#xD;
&#xD;
          -  Multidisciplinary conference (MDK) decision to offer the patient SRT&#xD;
&#xD;
          -  Signed Informed Consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients previously treated for prostate cancer with biochemical recurrence&#xD;
&#xD;
          -  Previous treatment with androgen deprivation therapy (ADT) after surgery&#xD;
&#xD;
          -  Previous pelvic radiotherapy&#xD;
&#xD;
          -  Patients with positive lymph nodes at surgery&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Carlsson</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefan Carlsson</last_name>
    <phone>0704871106</phone>
    <phone_ext>46</phone_ext>
    <email>stefan.carlsson@ki.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sanna Nyström</last_name>
    <email>sanna.nystrom@sll.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Göteborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ola Bratt</last_name>
      <email>ola.bratt@vgregion.se</email>
    </contact>
    <contact_backup>
      <last_name>Jon Kindblom</last_name>
      <email>jon.kindblom@vgregion.se</email>
    </contact_backup>
    <investigator>
      <last_name>Ola Bratt</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jon Kindblom</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Södersjukhuset</name>
      <address>
        <city>Stockholm</city>
        <zip>118 83</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chunde Li</last_name>
      <email>Chunde.Li@ki.se</email>
    </contact>
    <contact_backup>
      <last_name>Gunilla Sellerstam</last_name>
      <email>gunilla.sellerstam@sll.se</email>
    </contact_backup>
    <investigator>
      <last_name>Chunde Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Carlsson</last_name>
      <email>stefan.carlsson@ki.se</email>
    </contact>
    <contact_backup>
      <last_name>Katarina Hammarlund</last_name>
      <email>katarina.hammarlund@sll.se</email>
    </contact_backup>
    <investigator>
      <last_name>Stefan Carlsson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norrland's University Hospital</name>
      <address>
        <city>Umeå</city>
        <zip>901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karin Söderkvist, MD</last_name>
      <email>karin.soderkvist@umu.se</email>
    </contact>
    <contact_backup>
      <last_name>Camilla Thellenberg</last_name>
      <email>camilla.thellenberg@umu.se</email>
    </contact_backup>
    <investigator>
      <last_name>Karin Söderkvist, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Örebro University Hospital</name>
      <address>
        <city>Örebro</city>
        <zip>701 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Janusz Frey, MD PhD</last_name>
      <email>janusz.frey@regionorebrolan.se</email>
    </contact>
    <contact_backup>
      <last_name>Anna Messing-Eriksson</last_name>
      <email>anna.messing-eriksson@regionorebrolan.se</email>
    </contact_backup>
    <investigator>
      <last_name>Janusz Frey, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 9, 2021</study_first_submitted>
  <study_first_submitted_qc>March 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2021</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Stefan Carlsson</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>PSMA PET/CT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

